Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia (RIPAL)

Civil Hospices of Lyon

Status

Completed

Conditions

LYMPHOMA

Treatments

Biological: blood samplings

Study type

Observational

Funder types

Other

Identifiers

NCT02520895

2009.548

2010-A00591-38 (Other Identifier)

Details and patient eligibility

About

RIPAL is a prospective cohort study, which main goal is to define T and B immune repertoire diversity and magnitude in patients with non-Hodgkin lymphoma of high and low grade and chronic lymphocytic leukemia before and after treatment, and to evaluate the association of these parameters with clinical patient data and outcomes.

Full description

Constitution of a prospective cohort of 128 patients with 8 different groups of patients. This protocol is designed to evaluate a new tool for detecting the diversity of the repertoire T and B in patients with hematological disease. This in vitro diagnostic device is consisting of molecular biology kits Human ImmunTraCkeR® and Human Immun'IgH® and the analysis tool NDL®

Enrollment

98 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 Years and older
Subjects with a diagnosis of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, MALT, marginal zone, Waldenstrom's disease, chronic lymphocytic leukemia, T-cell lymphoma, anaplastic, cytotoxic or peripheral unspecified angioimmunoblastic.
Have signed an informed consent for participation in the study and preservation of blood samples for biomedical research.
Accept to appear in consultation biological samples at the sampling points corresponding to its group.
The benefits of social security.

Exclusion criteria

Subjects with a diagnosis of Hodgkin disease
Subjects with a diagnosis of T-prolymphocytic leukemia
Subjects with a diagnosis of Burkitt's lymphoma
Subjects with a diagnosis of lymphoblastic lymphoma
Subjects who had prior-treatment for hematological disease
Patients under judicial safeguards

Trial design

98 participants in 8 patient groups

large B lymphoma cells (group 1)

Description:

30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings

Treatment:

Biological: blood samplings

indolent B-cell lymphomas (group 2)

Description:

30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings

Treatment:

Biological: blood samplings

indolent B-cell lymphomas (group 3)

Description:

20 Patients with indolent B-cell lymphomas with lymphocytosis (\> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings

Treatment:

Biological: blood samplings

Lymphocytic Leukemia Chronic (LLC) (group 4)

Description:

20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings

Treatment:

Biological: blood samplings

T-cell lymphoma (group 5)

Description:

10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings

Treatment:

Biological: blood samplings

follicular lymphoma (group 6)

Description:

6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings

Treatment:

Biological: blood samplings

Lymphocytic Leukemia Chronic (LLC) (group 7)

Description:

6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings

Treatment:

Biological: blood samplings

Lymphocytic Leukemia Chronic (LLC) (group 8)

Description:

6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings

Treatment:

Biological: blood samplings